The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients With Overactive Bladder who Have Previously Been Managed With an Antimuscarinic: A Network Meta-analysis.
Urology
; 127: 1-8, 2019 05.
Article
em En
| MEDLINE
| ID: mdl-30790650
ABSTRACT
OBJECTIVE:
To compare the efficacy and safety of mirabegron and onabotulinumtoxinA in the management of treatment-experienced patients with overactive bladder.METHODS:
The network meta-analysis was based on evidence from a systematic literature review of randomized controlled trials and a post-hoc analysis of treatment-experienced subpopulations from mirabegron studies.RESULTS:
Nineteen trials described in 21 publications were included.CONCLUSION:
Overall, compared to mirabegron, there was some evidence that onabotulinumtoxinA was associated with improved outcomes, including reductions in the number of micturitions in a 24-hour period, and the number of incontinence episodes. However, mirabegron was associated with a lower risk of urinary tract infections compared with onabotulinumtoxinA.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Tiazóis
/
Toxinas Botulínicas Tipo A
/
Bexiga Urinária Hiperativa
/
Antagonistas de Receptores Adrenérgicos beta 3
/
Acetanilidas
Tipo de estudo:
Clinical_trials
/
Diagnostic_studies
/
Prognostic_studies
/
Systematic_reviews
Limite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Urology
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Canadá